The Centers for Medicare & Medicaid Services is asking the public for comment on whether to cover flurodexyglucose positron emission tomography, an imaging procedure, for diagnosing Alzheimer’s disease.
The University of California at Los Angeles School of Medicine requested CMS reconsider its decision in April not to cover it.
The questions include: What type of facility or setting is likely to offer the knowledgeable and experienced interdisciplinary staff needed to conduct a comprehensive assessment and render an accurate clinical diagnosis of dementia?
The Alzheimer’s Association said in January that it supports the use of FDG-PET for diagnosis when it is coupled with a thorough assessment by an experienced practitioner. The questions are located at www.cms.hhs.gov/coverage/id104.asp. Responses should be sent by March 31 to Samantha Richardson at [email protected].
